Testing PreveCol Blood Test as a Second Step for Early Detection of Colorectal Cancer in Adults Aged 50 to 69 with Positive FOBT Results

What this Trial Is About

Researchers are evaluating the efficiency of the PreveCol test as a second-line method to detect colorectal cancer and advanced adenomas in people aged 50 to 69 years who have a previous positive result from a fecal occult blood test FOBT. This low-risk interventional study aims to assess the tests effectiveness, impact, safety, participant preferences for screening methods, and patient-reported experience measures PREMs within the screening program. Participants will provide a blood sample for the PreveCol test before undergoing a screening colonoscopy. They will also complete two questionnaires one about their screening method preferences and another capturing their experience with the screening program. The study focuses on average-risk individuals who are asymptomatic and eligible for colonoscopy after a positive FOBT. During the study, researchers will collect blood samples, clinical data, and questionnaire responses. They will evaluate diagnostic values related to colorectal cancer and lesion detection over 12 months. The study includes safety monitoring and aims to understand the impact and preferences associated with colorectal cancer screening methods. Participation involves providing samples and completing questionnaires alongside routine colonoscopy.

Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection